Whereas low-count MBL hardly ever progresses to CLL, high-rely MBL progresses to CLL demanding therapy at a rate of 1% to 2% annually. Higher-depend MBL is distinguished from Rai 0 CLL depending on whether the B-cell count is earlier mentioned or under five × 109/L. Despite the fact that persons with both superior-count MBL and CLL Rai phase 0 are